Skip to main content
Premium Trial:

Request an Annual Quote

Appeal Denied

The US Supreme Court on Monday denied a request by Ono Pharmaceutical to review a federal appeals court decision that added two scientists as inventors on company patents covering a new cancer treatment technology, Reuters reports. The technology involves using T cell-targeting antibodies to stimulate immune responses against cancer cells and was developed primarily by Tasuku Honjo, who won a Nobel Prize in 2018 for his work. The Dana-Farber Cancer Institute sued Ono, along with patent licensee Bristol-Myers Squibb, in 2015 seeking to have its researcher Gordon Freeman and former Genetics Institute scientist Clive Wood, both of whom collaborated with Honjo, added to patents covering the technology. According to Reuters, a US District Court found in 2019 that both scientists had made significant enough contributions to Ono-controlled patents that they should be listed as coinventors — a decision upheld by a US Circuit Court the next year. Ono asked the Supreme Court to review the rule, but the court declined, Reuters reports.

Filed under

The Scan

Could Cost Billions

NBC News reports that the new Alzheimer's disease drug from Biogen could cost Medicare in the US billions of dollars.

Not Quite Sent

The Biden Administration likely won't meet its goal of sending 80 million SARS-CoV-2 vaccine doses abroad by the end of the month, according to the Washington Post.

DTC Regulation Proposals

A new report calls on UK policymakers to review direct-to-consumer genetic testing regulations, the Independent reports.

PNAS Papers on Mosquito MicroRNAs, Acute Kidney Injury, Trichothiodystrophy

In PNAS this week: microRNAs involved in Aedes aegypti reproduction, proximal tubule cell response to kidney injury, and more.